Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41198   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2005-002396-33
    Sponsor's Protocol Code Number:WA17044
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2006-03-01
    Trial results Removed from public view
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2005-002396-33
    A.3Full title of the trial
    A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate response to methotrexate.
    Studio internazionale, randomizzato, in doppio cieco, per valutare l efficacia e la sicurezza di vari regimi di ritrattamento con Rituximab in combinazione con metotrexate in pazienti con Artrite Reumatoide che hanno avuto una risposta inadeguata a metotrexate.
    A.4.1Sponsor's protocol code numberWA17044
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann- La Roche Ltd.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF.Hoffmann-La Roche Ltd.
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationRoche S.p.A.
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressViale G.B. Stucchi, 110
    B.5.3.2Town/ cityMonza
    B.5.3.3Post code20900
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 039 247 5070
    B.5.5Fax number+39 039 247 5085
    B.5.6E-mailitaly.info_cta@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mabthera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRituximab
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeNon Applicabile
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Rheumatoid Arthritis
    Artrite Reumatoide
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine if a second course with an increased dose of rituximab is associated with improved responses compared to re-treatment with the same dose.
    Valutare se un secondo ciclo con un aumentata dose di Rituximab e` associato ad un miglioramento della risposta rispetto al ritrattamento con la stessa dose.
    E.2.2Secondary objectives of the trial
    2. To determine response rates to two courses of 2 × 500 mg rituximab and two courses of 2 × 1000 mg rituximab. 3. To investigate the pharmacokinetics of rituximab associated with 2 courses of treatment.
    2.Valutare il grado di risposta in seguito a trattamento con due cicli di 2 x 500 mg e con due cicli di 2 x 1000 mg di Rituximab.3.Esplorare i parametri di farmacocinetica di Rituximab associati a 2 cicli di trattamento.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Able and willing to give written informed consent and comply with the requirements of the study protocol. 2. Patients with rheumatoid arthritis for at least 6 months, diagnosed according to the revised 1987 ACR criteria for the classification of rheumatoid arthritis. 3. Receiving treatment on an outpatient basis. 4. Swollen joint count (SJC) &#8805; 8 (66 joint count), and tender joint count (TJC) &#8805; 8 (68 joint count) at screening and baseline. 5. At screening, either CRP &#8805; 0.6 mg/dL (6 mg/L) OR ESR &#8805; 28 mm/h. 6. Minimum age 18 years. 7. Glucocorticoids &#8804; 10 mg/day prednisolone or equivalent permitted if stable for at least 4 weeks prior to baseline. 8. Use of NSAIDs is permitted if stable for at least 2 weeks prior to baseline. 9. For patients of reproductive potential (males and females), use of a reliable means of contraception (e.g. hormonal contraceptive, patch, intrauterine device, physical barrier) throughout study participation. Protocol WA17044 - 4 TARGET POPULATION (Cont.) 10. Must have an inadequate response to MTX and have been receiving and tolerating this at a dose of 10-25 mg/wk (p.o. or parenteral) for at least 12 weeks, with the last 4 weeks prior to baseline at a stable dose. MabThera (Rituximab) (Re-treatment should occur within 2 weeks. If more than 4 weeks elapses the patient is required to be reassessed for eligibility) Entry criterion for absolute neutrophil count (not below 1.5 × 103/&#956;L) was met at the last blood sample analysis. Patient has not developed contra-indications for receiving rituximab, such as: a) Any new or uncontrolled concomitant disease such as, but not limited to cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders. For patients who have entered the study and have been found to be HBsAg negative, HBcAb positive negative hepatitis B viral DNA (<29 IU/mL) and AST/ALT &#8804;2.5× ULN results within the last 12 weeks.
    1. Pazienti in grado di capire e firmare il consenso informato e di rispettare le procedure richieste dallo studio. 2. Pazienti con artrite reumatoide da almeno 6 mesi, diagnosticata secondo i criteri dell American College of Rheumatology (ACR) del 1987. 3. Pazienti che ricevono trattamenti ambulatorialmente. 4. Conta delle articolazioni tumefatte (SJC) &#61619; 8 (su 66 articolazioni) e conta delle articolazioni dolenti (TJC) &#61619; 8 (su 68 articolazioni) allo screening e al baseline. 5. Allo screening: Proteina C reattiva (PCR) &gt; 0.6 mg/dL (6 mg/L) oppure VES &gt; 28 mm/h. 6. Eta` minima: 18 anni. 7. Sono consentiti glucocorticoidi (&lt; 10 mg/giorno prednisolone o equivalente) purche` a dosaggio stabile da almeno 4 settimane prima del baseline. 8. E consentito l uso di FANS purche` a dosaggio stabile da almeno 2 settimane prima del baseline. 9. Pazienti in eta` fertile (donne e uomini) possono partecipare allo studio soltanto se utilizzano metodi contraccetivi affidabili (es. contraccettivi ormonali, cerotto, dispositivo intrauterino, barriera fisica) per tutta la durata della partecipazione allo studio. 10. I pazienti devono avere una risposta inadeguata al metotrexate (MTX) e devono aver ricevuto e tollerato MTX a un dosaggio di 10-25 mg/settimana (p.o. o parenterale) per almeno 12 settimane, con le ultime 4 settimane prima del baseline a dosaggio stabile. Il ritrattamenti dovrebbero essere somministrati entro 2 settimane dalla valutazione di eleggibilita` del paziente; se trascorressero piu` di 4 settimane, sarebbe necessario rivalutare l eleggibilita` del paziente. Criteri di inclusione da rispettare all ultimo prelievo di sangue: conta assoluta dei neutrofili non inferiore a 1.5 x 103/uL. I pazienti non devono aver sviluppato contro-indicazioni al trattamento con Rituximab, incluse: a. Patologie nuove o non-controllate come ad esempio (ma non limitatamente a) malattie cardiovascolari, del sistema nervoso, polmonari, renali, epatiche, endocrine o disordini gastrointestinali Per i pazienti entrati nello studio con HBsAg negativo, HBcAb positivo: negativita` alla valutazione del DNA del virus dell epatite B (&lt;29 UI/ml) e AST/ALT &lt; 2.5 ULN entro le ultime 12 settimane.
    E.4Principal exclusion criteria
    1. Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis or Felty s syndrome). Secondary Sjogren s syndrome or secondary limited cutaneous vasculitis with RA is permitted. 2. Functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis. 3. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., SLE, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome). 4. Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis (JRA) and/or RA before age 16. Exclusions Related to General Health 5. Any surgical procedure, including bone/joint surgery/ Synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 48 weeks of randomization. 6. Lack of peripheral venous access. 7. Pregnancy or lactation. 8. Significant cardiac or pulmonary disease (including obstructive pulmonary disease). 9. Evidence of significant uncontrolled concomitant disease such as nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator s opinion, would preclude patient participation. 10. Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection. 11. Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with i.v. anti-infectives within 4 weeks of baseline or oral anti-infectives within 2 weeks prior to baseline. 12. History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within 52 weeks of baseline. 13. History of serious recurrent or chronic infection (to check for chest infection a chest x-ray will be performed at screening if not performed within 12 weeks of screening). 14. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured). Protocol WA17044 - 5 TARGET POPULATION (Cont.) 15. Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments, in particular, joint pain and swelling (e.g. Parkinson s disease, cerebral palsy, diabetic neuropathy). 16. Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24 weeks prior to baseline.
    Criteri di Esclusione: Criteri di Esclusione correlati all Artrite Reumatoide 1. Malattie reumatiche autoimmuni diverse dall AR, o significativi coinvolgimenti a livello sistemico secondari ad AR (inclusi ma non limitati a vasculiti, fibrosi polmonare o sindrome di Felty). La concomitanza della sindrome di Sjogren secondaria o della vasculite cutanea circoscritta secondaria ad AR sono accettate. 2. Appartenenza alla IV classe di capacita` funzionale (criteri ACR). 3. Precedente anamnesi, o attuale malattia articolare infiammatoria diversa da AR (es. gotta, artrite reattiva, artrite psoriasica, spondiloartropatia sieronegativa, malattia di Lyme) o altra malattia sistemica autoimmune (es. LES, malattia infiammatoria intestinale, sclerodermia, miopatia infiammatoria, connettivite mista o altra sindrome concomitante). 4. Diagnosi di artrite idiopatica giovanile (JIA) o artrite reumatoide giovanile (JRA) e/o artrite reumatoide prima dei 16 anni. Criteri di Esclusione generali 5. Interventi chirurgici, compresi chirurgia/sinovectomia delle ossa/articolazioni (comprese fusioni o sostituzioni articolari) nelle 12 settimane prima del baseline o in caso di intervento pianificato entro le 48 settimane dalla randomizzazione. 6. Assenza di accesso venoso periferico. 7. Donne in stato di gravidanza o allattamento. 8. Significative malattie cardiache o polmonari (incluse malattie polmonari ostruttive). 9. Evidenza di severa patologia concomitante e non controllata a carico del sistema nervoso, renale, epatico, endocrino o gastrointestinale che, nell opinione del medico, possono precludere la partecipazione del paziente. 10. Immunodeficienza primaria o secondaria (precedente o attiva allo stato attuale), inclusa storia di infezione da HIV. 11. Infezioni attive di ogni tipo (escluse infezioni micotiche del letto ungueale), o qualsiasi episodio importante per cui e` stata necessaria una ospedalizzazione od una terapia endovena con anti-infettivi entro le 4 settimane precedenti il baseline oppure anti-infettivi orali nelle 2 settimane prima del baseline. 12. Storia di infezioni tissutali profonde (e.g. fasciti, ascessi, osteomieliti) entro 52 settimane dalla selezione. 13. Storia di infezioni serie ricorrenti o croniche (per controllare le infezioni del torace sara` effettuata una radiografia toracica allo screening, se non gia` effettutata nelle 12 settimane prima dello screening). 14. Storia di neoplasie, inclusi tumori solidi, neoplasie ematologiche e carcinoma in situ (eccetto carcinoma della cute a cellule basali e cellule squamose gia` asportato e guarito). 15. Patologie neurologiche (congenite o acquisite), vascolari o sistemiche che potrebbero interferire con la valutazione dell efficacia, in particolare, con il dolore articolare e la tumefazione (es. morbo di Parkinsons, paralisi cerebrale, neuropatia diabetica). 16. Abuso di alcool o droghe o storia di etilismo o tossicodipendenza nelle 24 settimane precedenti il baseline.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients with an ACR20 response at Week 48.
    Proporzione di pazienti con una risposta ACR20 alla settimana 48.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    differente dose e regime di trattamento
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned13
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA61
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    I pazienti riceveranno il trattamento per un max. di 240 settimane o fino alla disponibilita` commerciale di rituximab per questa popolazione di pazienti o il 31 Dicembre 2010,seguito da un follow up di safety di almeno 1 anno.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 224
    F.4.2.2In the whole clinical trial 375
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2005-11-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2005-11-04
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2013-03-25
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA